Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
NVCT | US
0.27
3.19%
Healthcare
Biotechnology
30/06/2024
14/04/2026
8.73
8.56
8.87
8.56
Nuvectis Pharma Inc. a biopharmaceutical company focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company develops NXP800 a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900 a small molecule drug candidate that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma Inc. and changed its name to Nuvectis Pharma Inc. in July 2021. Nuvectis Pharma Inc. was incorporated in 2020 and is based in Fort Lee New Jersey.
View LessLow Market Beta (-0.4 to 0.8)
Microcap (<300M USD)
Rich in Valuation (Price to Book > 8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
29.1%1 month
41.7%3 months
42.3%6 months
52.6%-
-
11.32
-
-
-7.38
-
-
-
162.84M
162.84M
-
-
-
-
-128.44
11.11
10.43
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.42
Range1M
2.13
Range3M
2.71
Rel. volume
0.78
Price X volume
404.95K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Fennec Pharmaceuticals Inc | FENC | Biotechnology | 6.25 | 176.11M | 5.40% | 64.86 | -2193.44% |
| Protalix BioTherapeutics Inc | PLX | Biotechnology | 2.36 | 173.56M | 3.06% | n/a | 91.50% |
| OABI | OABI | Biotechnology | 1.46 | 172.52M | 0.00% | n/a | 8.27% |
| OBIO | OBIO | Biotechnology | 4.51 | 170.59M | 4.88% | n/a | 3.29% |
| Adagene Inc. | ADAG | Biotechnology | 3.81 | 168.67M | -0.78% | n/a | 36.29% |
| Connect Biopharma Holdings Limited American Depositary Shares | CNTB | Biotechnology | 3.05 | 168.52M | 7.77% | n/a | 0.29% |
| Codexis Inc | CDXS | Biotechnology | 2.37 | 168.10M | 3.04% | n/a | 69.22% |
| Candel Therapeutics Inc. Common Stock | CADL | Biotechnology | 5.1 | 163.63M | 4.72% | n/a | -186.13% |
| BriaCell Therapeutics Corp. Common Shares | BCTX | Biotechnology | 4.54 | 162.93M | 3.65% | n/a | 0.00% |
| ProQR Therapeutics N.V | PRQR | Biotechnology | 1.99 | 162.54M | 10.56% | n/a | 53.73% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 10.29 | 165.22M | 3.00% | n/a | 286.96% |
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 34.41 | 98.82M | -0.81% | 5.16 | 19.82% |
| Virco Mfg. Corporation | VIRC | Building Products & Equipment | 6.06 | 98.71M | 3.59% | 9.09 | 39.79% |
| Saga Communications Inc | SGA | Broadcasting - Radio | 11.98 | 75.01M | 2.45% | 14.48 | 7.10% |
| ILAG | ILAG | Building Products & Equipment | 3.6 | 65.02M | 1.12% | n/a | 5.48% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 14.75 | 22.46M | 41.83% | n/a | 204.46% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.91 | 13.30M | 3.42% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.623 | 12.04M | 3.83% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.32 | 3.37M | -0.75% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.2149 | 2.05M | -5.58% | n/a | 19.98% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -7.38 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 11.32 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 42.32 | - | Lower Risk |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 162.84M | - | Emerging |